Mechanistically, the CARD11-PIK3R3 fusion gene amplified CARD11-BCL10-MALT1 (CBM) signaling in an antigen-dependent manner, thereby potentiating the anti-tumor efficacy of CAR T cells across various immunotherapy-refractory models. The gene discussed is CARD11; the disease is neoplasm.